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 The serum hyaluronic acid (HA) levels are associated 
with liver regeneration after hepatectomy. In the present 
study, the HA concentrations were examined to evaluate 
the relationship with changes of hepatic volume after right 
portal vein embolization (PVE). The HA level of serum sam-
ples from 10 patients who underwent PVE before 
hepatectomy of the right lobe was measured, and the re-
sults were compared to the changed volume of embolized 
right lobe and unembolized left lobe of the liver. The mean 
serum HA level in patients with chronic viral liver disease 
(CVLD) (202+/-118 ng/ml) was significantly greater than in 
those without CVLD (70+/-24 ng/ml) (p<0.05). The volume 
of embolized liver decreased 72+/-96 CM3 (-8.9+/-5.5 %), 
while the volume of unembolized liver increased 106+/-67 
CM3 (+8.9+/-5.5 %) 2 weeks after PVE. HA concentrations 
after 2 weeks of PVE (296+/-216 ng/ml) tended to be 
greater than that before PVE (134+/-108 ng/ml) but not 
statistically significant (p=0.105). There were no 
correlations between serum HA levels before PVE and the 
changes of hepatic volume in embolized and unembolized 
lobe after PVE. Our results indicate that the measurement 
of HA level is not useful for predicting the effect of PVE. 
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Introduction
ume for resection and initiate hypertrophy of the fu-
ture remnant liver. The preoperative PVE is safe and 
minimize postoperative liver failure after major sur-
gery."' Hepatic functions of remnant liver are main-
tained after PVE.4'' 
 The serum level of hyaluronic acid (HA) is a sensi-
tive marker of hepatic fibrosis and reflects the func-
tional liver reserve in patients with chronic hepatitis 
or cirrhosis including our previous pilot study. 6 - s As 
markers of hepatic fibrosis, serum level of collagen or ex-
tra-cellular matrix, such as the type III aminoterminal 
peptide of procollagen (PIIIP) or laminin have been 
measured as well."" However, HA is specifically me-
tabolized by endothelial cells of hepatic sinusoids and 
increased serum HA level reflects damage of hepatic 
endothelial cells." Therefore, serum HA level reflects 
the functional liver reserve of non-parenchymal liver 
cells. Our study revealed that the serum HA level at 
pre- and post-operative state was significantly corre-
lated with the regenerated volume of remnant liver 
after lobectomy.s This indicates that serum HA level 
is a useful marker for regeneration after major 
hepatectomy. Yachida et al. reported a correlation be-
tween serum HA level and hypertrophic ratio subse-
quent to PVE.12 
 In the present study, we also evaluated the useful-
ness of serum HA as an index of hypertrophy of rem-
nant liver after PVE by measuring its level before 
right or extended right lobectomy of the liver.
 To overcome impaired hepatic functions after major 
hepatectomy, portal vein embolization (PVE) tech-
nique, which was firstly published by Makuuchi et al.,' 
has been applied to reduce the expected hepatic vol-
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 The subjects were 10 patients with hepato-biliary 
diseases who underwent right lobe or extended right 
lobe hepatectomy in the First Department of. Surgery, 
Nagasaki University School of Medicine between 
January 1996 and September 2001. They included 9
Atsushi Nanashima et al : Hyaluronate before Portal Embolization
males and a female with a mean age of 63 ± 7 years 
(range, 61-73 years). Hepato-biliary carcinoma included 
5 hepatocellular carcinomas, 2 gall bladder carcino-
mas, 2 hilar bile duct cancers, and a intra-hepatic 
cholangiocarcinoma. The background liver abnormal-
ity included chronic viral liver diseases in 5, obstruc-
tive jaundice in 2 and liver with normal function in 3 
patients. These patients were divided into two groups 
of chronic viral liver disease (CVLD) consisting of 
chronic hepatitis and cirrhosis (n=5), and non-CVLD 
consisting of normal and icteric liver (n=5). 
 In our institute, the volume of liver tissue to be 
resected during surgery is calculated based on the re-
sults of ICG R15 and Takasaki's formula. 13 The vol-
ume of the liver section to be resected excluding 
tumor volume is then measured by CT volumetry, in 
which serial liver scans at 1.0 cm intervals were taken 
and summed (cm 3 ).14 The pre-operative PVE was ap-
plied in patients who would undergo major hepatectomy, 
in case the expected ratio of resected volume in the 
whole liver volume is more than 60% in patients with-
out chronic liver disease, or more than 50% in patients 
with chronic hepatitis or cirrhosis by our protocol of 
liver resection. The study design was approved by the 
Ethics Review Board of our institution and a signed 
consent was obtained from each subject.
morning from each patient at the following time inter-
vals: 1) when the patient was at a stable condition 
during hospitalization, and 2) 14 post-operative days 
after PVE. The blood sample was immediately centri-
fuged at 3,500G for 15 minutes, and 0.5 ml of serum 
was stored at -80°C. HA was assayed using the sand-
wich binding protein assay by SRL, Inc. (Tokyo, 
Japan) and the normal value was determined as less 
than 50 ng/ml. The serum HA level was compared 
with the changed volume of the embolized and 
unembolized liver at day 14 after PVE.
Statistical analysis
 Data were expressed as a mean ± SD. Data of dif-
ferent groups were compared using one-way analysis 
of variance (ANOVA) and examined by Student's t-
test. Correlations between two parameters were exam-
ined by calculating the Pearson's correlation coeffi-
cient. A two-tailed P value < 0.05 was considered 
significant. The StatView Software for Windows, 
Version 5.0 (SAS Institute, Inc., Cary, NC) was used 
for all statistical analyses.
Results
Technique of portal vein embolization and evaluation
 Two approaches of access to right portal vein were 
a direct catheterization of ileocolic vein (n=4) and 
percutaneous transhepatic puncture (n=6) according to 
the coarse of the portal vein and the patient condi-
tions. Portal pressures before and after PVE were 
measured to estimate the efficacy of embolization. 
Substances used for embolization in our series were 
lg of absorbable gelatin sponge powder (Gelfoam®; 
Upjohn, Kalamazoo, MI, USA) and 5,000 units (5m1) of 
liquid thrombin (Sankyou Co., Tokyo, Japan) mixed in 
the contrast media. Permanent embolization materials 
have never been used. Embolization was completed 
when the entire right portal vein was completely oc-
cluded. 
 At 14 days after PVE, the hepatic volume of the 
unembolized lobe and embolized lobe (lobe to be 
resected) were reassessed by CT volumetry, and liver 
function tests including ICG R15 were also assessed 
again. Surgical resection of the liver was performed at 
21 days after PVE.
Measurement of serum HA
Peripheral blood samples were collected in the early
Patient outcome after PVE
 Most of the patients had mild fever-up and mild ele-
vation of serum AST and ALT levels (data not shown) 
for the first week and, however, recovered to the nor-
mal values at 14 days after PVE. No patients experi-
enced severe complications or death. The value of ICG 
R15 did not significantly alter between pre- and post-
PVE (11.4+/-4.9 % and 13.5+/-9.6 %, p=0.438). Therefore, 
all patients kept being scheduled to undergo right or 
extended right lobectomy of the liver.
Relationship between serum HA level and the liver vol-
ume after PVE
 The mean serum HA concentration in all patients 
was 134 ± 108 ng/ml, and that in patients with 
chronic viral liver diseases (202±118 ng/ml) was sig-
nificantly higher than in patients with normal and 
icteric liver (70±24 ng/ml) (p=0.048). The actual vol-
ume and its proportional ratio were shown in Table 1. 
After PVE, the proportional ratio of the embolized 
right lobe was significantly decreased, and, on the 
other hand, the volume and the proportional ratio of 
the unembolized left lobe were significantly increased 
in patients with both non-CVLD and CVLD. Serum
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HA levels after 2 weeks of PVE (296+/-216 ng/ml) 
tended to be greater than that before PVE (134+/-108 
ng/ml) but not statistically significant (p=0.105). 
Before PVE, serum HA level significantly correlated 
with the value of ICG R15 (r=-0.509, p<0.05). However, 
on the other hands, serum HA level after 2 weeks of 
PVE did not correlate with the value of ICG R15 at 
the same stage (r=-0.358, p=0.760). 
 In Table 2, no significant correlation between the 
serum HA level before PVE and changes of the actual 
volume and the proportional ratio of embolized and 
unembolized lobes after PVE was observed in patients 
with either non-CVLD or CVLD.
Table 1. Changed volume of embolized and unembolized 
liver after PVE
a) Actual volume 
                     Pre-PVE 2) (cm) Post-PVE (cm) Changed volume (cm) 
    Embolized lobe 648+/-149 576+/-2153) -72+/-96
      Non-CVLD') (n=5) 748+/-216 697+/-260 -51+/-79 
        CVLD (n=5) 573+/-131' 486+/-119`0 -87+/-107 
  Non-embolized lobe 428+/-167 534+/-1703) 106+/-67 
      Non-CVLD (n=5) 386+/-145 503+/-1823> 117+/-66 
       CVLD (n=5) 460+-180 558+/-1643) 98+/-69 
b) Proportional ratio of lobe in the whole liver 
                       Pre-PVE(%) Post-PVE (%) Changed ratio (%) 
     Embolized lobe 60.5+/-9.8 51.6+/- 9.83) -8.9+/-5.5
       Non-CVLD (n=5) 66.2+/-3.3 57.9+/- 4.93) -8.3+/-3.2 
         CVLD (n=5) 56.2+/- 10.9* 46.9+/-10.03) ** -9.3+/-6.8 
   Non-embolized lobe 39.5+/-9.8 48.4+/- 9.83) 8.9+/-5.5 
       Non-CVLD (n=5) 33.8+/-3.3 42.2+/- 4.93) 8.3+/-3.2 
        CVLD (n=5) 43.8+-10.9* 53.1+/-10.03)** 9.3+/-6.8 
1) chronic viral liver disease 2) portal vein embolization 3) p<0.0l vs pre-PVE 4) p<0.05 vs pre-PVE 
*: p<0.05 vs non-CVLD **: p<O.Ol vs non-CVLD
Table 2. Correlation between serum HA level and changed 
volume of embolized and unembolized liver after PVE
                      Correlation with P value Correlation with P value 
                         actual volume proportional ratio 
    Embolized lobe 0.043 2> 0.910 0.106 0.779 
     Non-CVLD) (n=5) 0.062 0.930 0.632 0.292 
       CVLD (n=5) 0.503 0.434 0.317 0.642 
  Non-embolized lobe -0.190 0.611 -0.106 0.779 
     Non-CVLD (n=5) -0.022 0.976 -0.632 0.292 
        CVLD (n=5) 0.463 0.478 -0.317 0.642 
I) chronic viral liver disease 2) correlation coefficient (r )
Discussion
 Measurement of serum hyaluronic acid level is a 
good index of liver function and has been recently 
used to evaluate indication or prediction of complica-
tions after liver resection and transplantation."," 
Serum HA levels were significantly high in patients 
with pre-cirrhotic and cirrhotic stage of chronic liver 
disease because higher HA level was caused by severe 
fibrosis and severe damage of endothelial cells in he-
patic sinusoid.""" Therefore, serum HA levels re-
flected the severity of liver disease. In the present 
study, the serum HA level was also higher in patients 
with chronic viral liver disease compared to those
with normal liver and obstructive jaundice. 
 After major hepatectomy, regeneration of the rem-
nant liver is the most important factor in the recov-
ery of liver function and overcoming hepatic failure." 
Ogata et al." and our group' previously reported that 
the presence of high preoperative serum HA concen-
tration was significantly associated with inhibition of 
hepatic regeneration after hepatectomy in patients 
with both normal liver and chronic liver diseases. 
Thus, it is possible to predict the regeneration capac-
ity of the damaged liver before operation by measur-
ing serum HA levels. As described above, nowadays 
PVE technique has been preferably applied to acceler-
ate the hypertrophy of the remnant liver in order to 
prevent hepatic failure after major hepatectomy.2' 3 
Although the regeneration activity of the liver after 
PVE may be based on any functional liver reserve, 
distinct predictive markers for regeneration by this 
technique have not been clarified so far. We hypothe-
sized that the serum HA marker might be useful for 
this marker after PVE as well as in cases of 
hepatectomy. In the present study, the effect of PVE 
showing by changes of hepatic volume was significant 
and no patient had hepatic failure after liver resection. 
Changes of hepatic volume after PVE seemed not to 
be different between non-CVLD and CVLD. It has 
been reported that PVE does not lead severe liver 
damage.' Although the white blood cell counts, CRP, 
transaminase levels etc. transiently deteriorated after 
PVE, the liver functions were almost normalized after 
2 weeks (data not shown in the present study). ICG 
R15 tended to worsen causing the decrease of clear-
ance of ICG by the hepatic flow alteration but not sig-
nificant change. The plan of right lobectomy or ex-
tended right lobectomy of the liver had not been 
changed at 2 weeks after PVE in all patients. Serum 
HA level did not significantly increase at 2 weeks 
after PVE in the present study, and, therefore, damage 
of endothelial cell function by PVE might not be se-
vere. Serum HA level significantly correlated with the 
ICG R15 value as we reported previously,' and, how-
ever, HA level after PVE did not correlated with the 
ICG R15 value after PVE. By these results, hepatic 
blood flow alteration might not be associated with the 
clearance of HA and the damage of endothelial cell of 
hepatic sinusoid by PVE was minimized. 
 Unfortunately, the correlations between serum HA 
levels and changes of hepatic volume after PVE was 
not observed. In case of hepatectomy, the remnant 
liver may remarkably regenerate to maintain liver 
functions because the absolute hepatic volume de-
creases. While, in case of PVE, the embolized liver still 
maintain the arterial blood flow and hepatic functions,
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and, therefore, the regeneration is probably slower 
compared to that after surgical resection. Furthermore, 
we speculate that the mechanism of regeneration of 
hepatic cells after PVE is different from that after 
major hepatic resection. Therefore, the serum HA level 
might not correlate with the changes of hepatic vol-
ume after PVE. By our results, it is indicated that the 
serum HA level before PVE is not a useful marker for 
prediction of the PVE affect contrary to the previous 
our results in cases after hepatectomy.8 
 In conclusion, we have demonstrated in the present 
study that serum HA level before PVE was not associ-
ated with the changes of embolized and unembolized 
lobe after PVE. It is clarified that. the measurement of 
serum HA level before PVE is not useful to evaluate 
the efficacy of PVE technique.
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